ArticleEuropean heart journal open2025

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity:

Mamas A Mamas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.